LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 140

Search options

  1. Article ; Online: Framework

    Curtiss, Frederic R / Fry, Richard N / Avey, Steven G

    Journal of managed care & specialty pharmacy

    2020  Volume 26, Issue 7, Page(s) 798–816

    Abstract: ... as the educational and philanthropic arm of the Academy of Managed Care Pharmacy; author Frederic R. Curtiss ...

    Abstract Objective: To review the literature on the subject of quality improvement principles and methods applied to pharmacy services and to describe a framework for current and future efforts in pharmacy services quality improvement and effective drug therapy management.
    Background: The Academy of Managed Care Pharmacy produced the
    Findings: There are many opportunities for quality improvement in clinical, service, and cost outcomes related to drug therapy management. These may include patient safety; incidence of medical errors; adverse drug events; patient adherence to therapy; attainment of target goals of blood pressure, glucose, and lipid levels; risk reduction for adverse cardiac events and osteoporotic-related fractures; patient satisfaction; risk of hospitalization or mortality; and cost of care. Health care practitioners can measure improvements in health care quality in several ways including (a) a
    Conclusions: Quality improvement in health care services in the United States will be made in incremental changes that rely on a structure-process-outcome model. The
    Disclosures: Authors Richard N. Fry and Steven G. Avey are employed by the Foundation for Managed Care Pharmacy, a nonprofit charitable trust that serves as the educational and philanthropic arm of the Academy of Managed Care Pharmacy; author Frederic R. Curtiss performed the majority of work associated with this manuscript prior to becoming editor-in-chief of the
    MeSH term(s) Humans ; Managed Care Programs/standards ; Managed Care Programs/trends ; Medication Errors/prevention & control ; Medication Errors/trends ; Medication Reconciliation/standards ; Medication Reconciliation/trends ; Patient Satisfaction ; Pharmaceutical Services/standards ; Pharmaceutical Services/trends ; Pharmacists/standards ; Pharmacists/trends ; Professional Role ; Quality Improvement/standards ; Quality Improvement/trends ; Quality of Health Care/standards ; Quality of Health Care/trends
    Language English
    Publishing date 2020-06-11
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2376-1032
    ISSN (online) 2376-1032
    DOI 10.18553/jmcp.2020.26.7.798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Omalizumab and other new drug therapies occupy a small space in asthma disease management.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2009  Volume 15, Issue 3, Page(s) 289–293

    MeSH term(s) Adolescent ; Adult ; Anti-Asthmatic Agents/therapeutic use ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Asthma/drug therapy ; Asthma/immunology ; Etanercept ; Humans ; Immunoglobulin E/metabolism ; Immunoglobulin G/therapeutic use ; Omalizumab ; Patient Selection ; Practice Guidelines as Topic ; Receptors, Tumor Necrosis Factor/therapeutic use ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunoglobulin G ; Receptors, Tumor Necrosis Factor ; Tumor Necrosis Factor-alpha ; Omalizumab (2P471X1Z11) ; Immunoglobulin E (37341-29-0) ; golimumab (91X1KLU43E) ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2009-02-03
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2009.15.3.289
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Irritable bowel syndrome and antidepressants.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2008  Volume 14, Issue 9, Page(s) 882–885

    MeSH term(s) Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Clinical Trials as Topic ; Depression/complications ; Depression/drug therapy ; Humans ; Irritable Bowel Syndrome/complications ; Irritable Bowel Syndrome/diagnosis ; Irritable Bowel Syndrome/drug therapy ; Irritable Bowel Syndrome/economics
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2008-06-18
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2008.14.9.882
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Atopic march to a dead end or does the theory really have legs?

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 13, Issue 9, Page(s) 810–811

    MeSH term(s) Dermatitis, Atopic/physiopathology ; Disease Progression ; Humans ; Hypersensitivity, Immediate/complications ; Hypersensitivity, Immediate/etiology ; Hypersensitivity, Immediate/physiopathology ; Terminology as Topic
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2007.13.9.810
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Perspectives on the "generic cliff"--pushing and falling.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 14, Issue 3, Page(s) 318–321

    MeSH term(s) Commerce ; Drug Costs ; Drug Industry/economics ; Drug Industry/organization & administration ; Drugs, Generic/economics ; Humans ; Managed Care Programs/economics ; Managed Care Programs/organization & administration ; Practice Patterns, Physicians'/economics ; United States
    Chemical Substances Drugs, Generic
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2008.14.3.318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 14, Issue 2, Page(s) 195–197

    MeSH term(s) Analgesics, Opioid/therapeutic use ; Buprenorphine/therapeutic use ; Clinical Trials as Topic ; Drug Combinations ; Humans ; Insurance Claim Review ; Naloxone/therapeutic use ; Narcotic Antagonists/therapeutic use ; Opioid-Related Disorders/drug therapy
    Chemical Substances Analgesics, Opioid ; Drug Combinations ; Narcotic Antagonists ; Naloxone (36B82AMQ7N) ; Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2008.14.2.195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: HEDIS, beta-blockers, and what more can be done to improve secondary prevention in ACS.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 14, Issue 3, Page(s) 316–317

    MeSH term(s) Acute Coronary Syndrome/complications ; Acute Coronary Syndrome/drug therapy ; Adrenergic beta-Antagonists/therapeutic use ; Cardiovascular Diseases/prevention & control ; Humans ; Managed Care Programs/organization & administration ; Practice Guidelines as Topic ; Practice Patterns, Physicians'/standards ; Quality Assurance, Health Care/methods ; United States
    Chemical Substances Adrenergic beta-Antagonists
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2008.14.3.316
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 13, Issue 5, Page(s) 429–430

    MeSH term(s) Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Chemical and Drug Induced Liver Injury/etiology ; Community-Acquired Infections/drug therapy ; Drug Labeling/legislation & jurisprudence ; Humans ; Insurance Claim Reporting ; Ketolides/adverse effects ; Ketolides/therapeutic use ; Liver Failure/chemically induced ; Patient Care Team ; Pneumonia, Bacterial/drug therapy ; United States ; United States Food and Drug Administration
    Chemical Substances Anti-Bacterial Agents ; Ketolides ; telithromycin (KI8H7H19WL)
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Case Reports ; Journal Article ; Comment
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2007.13.5.429
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Outcomes of sword swallowing and pharmaceutical step-therapy interventions.

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 13, Issue 3, Page(s) 284–286

    MeSH term(s) Angiotensin II Type 1 Receptor Blockers/economics ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/economics ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/economics ; Antihypertensive Agents/therapeutic use ; Cost-Benefit Analysis ; Drug Costs ; Eligibility Determination ; Health Care Costs ; Humans ; Hypertension/drug therapy ; Hypertension/economics ; Insurance Claim Review/economics ; Insurance Claim Review/organization & administration ; Insurance, Pharmaceutical Services/economics ; Managed Care Programs/economics ; Managed Care Programs/organization & administration ; Outcome Assessment, Health Care ; Treatment Outcome ; United States
    Chemical Substances Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2007.13.3.284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?

    Curtiss, Frederic R

    Journal of managed care pharmacy : JMCP

    2007  Volume 13, Issue 3, Page(s) 287–289

    MeSH term(s) Antibodies, Monoclonal/economics ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Cost-Benefit Analysis ; Drug Costs ; Economics, Pharmaceutical ; Glatiramer Acetate ; Health Care Costs ; Humans ; Immunologic Factors/economics ; Immunologic Factors/therapeutic use ; Interferon beta-1a ; Interferon beta-1b ; Interferon-beta/economics ; Interferon-beta/therapeutic use ; Models, Econometric ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/economics ; Natalizumab ; Outcome Assessment, Health Care ; Patient Compliance ; Patient Satisfaction ; Peptides/economics ; Peptides/therapeutic use ; Quality-Adjusted Life Years ; Research Design ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunologic Factors ; Natalizumab ; Peptides ; Interferon beta-1b (145155-23-3) ; Glatiramer Acetate (5M691HL4BO) ; Interferon-beta (77238-31-4) ; Interferon beta-1a (XRO4566Q4R)
    Language English
    Publishing date 2007-02-14
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2022394-8
    ISSN 1944-706X ; 1083-4087
    ISSN (online) 1944-706X
    ISSN 1083-4087
    DOI 10.18553/jmcp.2007.13.3.287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top